Stock Financial Ratios, Dividends, Split History

FENC / Fennec Pharmaceuticals Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price10.69
Volume32,200.00
Market Cap ($M)197.71
Enterprise Value ($M)178.76
Book Value ($M)25.66
Book Value / Share1.39
Price / Book7.99
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 18,411,000
Weighted Average Number Of Shares Outstanding Basic 15,014,000
Weighted Average Number Diluted Shares Outstanding Adjustment 0
Common Shares Outstanding 18,464,706
Weighted Average Number Of Diluted Shares Outstanding 15,014,000
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.26
Return on Assets (ROA)-1.77
Return on Equity (ROE)-1.97
Balance Sheet (mrq) ($M)
Assets26.84
Liabilities1.17
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues0.00
Revenue From Grants0.00
Operating Income-6.95
Net Income-7.05
Earnings Per Share Basic-0.47
Earnings Per Share Basic And Diluted-0.22
Earnings Per Share Diluted-0.47
Cash Flow Statement (mra) ($M)
Cash From Operations-3.64
Cash from Investing0.00
Cash from Financing0.00
Identifiers and Descriptors
CUSIP00686R200
Central Index Key (CIK)1211583

Split History

Stock splits are used by Fennec Pharmaceuticals Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Your Daily Pharma Scoop: Esperion Gains On Data, AnaptysBio's ANB020, Tesaro Reports Promising Data

2018-03-28 seekingalpha
Esperion Therapeutics (NASDAQ:ESPR) shares have moved up sharply after the company announced top-line results from a phase 2 study (1002-039) evaluating the LDL-C lowering efficacy and safety of bempedoic acid 180 mg added-on to stable background therapy of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in 58 patients with hypercholesterolemia. (158-3)

Fennec's stock soars further after PEDMARK receives 'breakthrough therapy' designation - MarketWatch

2018-03-27 marketwatch
Shares of Fennec Pharmaceuticals Inc. FENC, -0.37% were indicated up over 12% in premarket trade Tuesday, after the specialty pharmaceutical company said its PEDMARK to prevent cisplatin ototoxicity in pediatric patients with liver cancer was granted a "breakthrough therapy" designation by the Food and Drug Administration. Breakthrough therapy designation is given when there is preliminary clinical evidence that a treatment represents substantial improvement over available therapies, and includes fast-track program features. (2-0)

Top Analyst Upgrades and Downgrades: Apollo, ADM, Cigna, HubSpot, Intuit, Newmont, Nike, SAP, Time Warner and More

2018-03-12 247wallst
Stocks were up big on Friday after a solid jobs report and less wage inflation. The major stock market indexes were indicated to open marginally higher on Monday as well. The bull market is now more than nine years old, and the one trend that has prevailed for more than five years has been for investors to buy all the big pullbacks. Investors also still have to decide how they want to be positioned for the rest of 2018 and beyond. (187-4)

CUSIP: 00686R200